Persson, Jonas
Puuvuori, Emmi
Zhang, Bo
Velikyan, Irina
Åberg, Ola
Müller, Malin
Nygren, Per-Åke
Ståhl, Stefan
Korsgren, Olle
Eriksson, Olof
Löfblom, John
Funding for this research was provided by:
Uppsala University
Article History
Received: 20 April 2021
Accepted: 19 August 2021
First Online: 27 September 2021
Change Date: 29 December 2021
Change Type: Update
Change Details: The original online version of this Article was revised: In the original version of this Article the Supplementary Information file contained tracked changes. The original Article has been corrected.
Competing interests
: J.P. holds intellectual property (IP) relating to the CD69 targeting Affibody molecules. E.P. have no conflicts of interest to disclose. B.Z. have no conflicts of interest to disclose. I.V. have no conflicts of interest to disclose. O.Å. have no conflicts of interest to disclose. M.M. have no conflicts of interest to disclose. PÅ.N. have no conflicts of interest to disclose. S.S. holds intellectual property (IP) relating to the CD69 targeting Affibody molecules. O.K. holds intellectual property (IP) relating to the CD69 targeting Affibody molecules and is a co-founder of Antaros Tracer AB. O.E. holds intellectual property (IP) relating to the CD69 targeting Affibody molecules, is an employee of Antaros Medical AB and is a co-founder of Antaros Tracer AB. J.L. holds intellectual property (IP) relating to the CD69 targeting Affibody molecules.